Abstract
No public abstract is available from the verified source records.
Yan-Ruide Li
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies
10.1186/s12967-023-04575-9 · 2023
Allogeneic immunotherapy
10.1038/s44222-026-00468-w · 2026
CAR T cell combination therapies to treat cancer
10.1016/j.ccell.2024.07.002 · 2024
An engineered PD-1 receptor-1 based CAR that binds anti-PD-1 antibodies but not PD-L1 to enhance T-cell functionality
2026
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
10.1186/s12943-021-01489-2 · 2022
PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas
10.1038/nrclinonc.2016.168 · 2017
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
10.1038/s41571-019-0297-y · 2020
A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
10.1158/0008-5472.can-15-2524 · 2016
In vivo CAR engineering for immunotherapy
10.1038/s41577-025-01174-1 · 2025
Engineering an in vivo charging station for CAR-redirected invariant natural killer T cells to enhance cancer therapy
10.1038/s41551-026-01629-3 · 2026
No additional external references are available.